other material
confidence high
sentiment positive
materiality 0.85
Nkarta reports 60% CR for NKX101 in AML; 83% ORR for NKX019 in NHL
Nkarta, Inc.
- NKX101: 3/5 AML patients at 1B/1.5B cells x3 achieved CR (60%); 2 of 3 CRs are MRD negative.
- NKX019: 5/6 NHL patients at 1B cells x3 achieved response (83% ORR); 3/6 CR (50% CR).
- No CRS, neurotoxicity, or GvHD reported for either program; safety profile favorable.
- Both programs advancing to 1.5B cells x3 dose regimen for recommended Phase 2 dose.
- Phase 1 trials continue enrolling; updated data to be submitted to future medical meeting.